APBA1

Across TCGA pan-cancer cohorts, APBA1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated APBA1 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher APBA1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated APBA1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

STAD, LGG, and LIHC are the cancer types where APBA1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	III,IV	1.000	0.336	.025	15	view →
LGG	DFS	Median	All	0.126	0.834	<.001	14	view →
LIHC	DFS	Median	II,III,IV	0.081	0.463	.017	12	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

APBA1–STAD (DFS)

Open the STAD breakdown →